Healthcare staff are the group with the very best threat of COVID-19 transmission. The sickness of healthcare staff poses a threat to sufferers admitted to the hospital, colleagues and households in addition to their very own well being. On this examine, it was aimed to find out the chance evaluation and the elements related to threat standing of an college hospital healthcare staff after dangerous COVID-19 contact. The info of the descriptive examine have been obtained from 773 follow-up information of 555 healthcare staff who utilized with COVID-19 dangerous contact between 06.04-10.05.2020. With the bodily enchancment of the remaining areas of the staff and the association of the breaks, the dangerous contact between colleagues within the social areas shall be lowered.
Workers who have been optimistic for RT-PCR evaluated as “sufferers” and others as “dangerous contact”. Danger evaluation was labeled as no threat, low, medium and excessive threat contact in keeping with the “Algorithm of Evaluation of Well being Employees with COVID-19 Contact” of the Ministry of Well being. The connection between the chance ranges of the individuals and their demographic and office traits and their utilization of non-public safety have been evaluated. Imply, normal deviation, share, chi-square and ANOVA checks have been used within the evaluation of the information. The common age of the healthcare staff was decided as 34.4 ± 7.6 years. It was decided that 56.2% of those that had contact have been feminine, 62.9% have been married and 17.5% had a further illness.
It was decided that 45.6% of the dangerous contacts have been nurses, 18.4% have been supportive personnel and 16.9% have been medical doctors. Whereas 46.5% of the contacts have been discovered as medium, 28.0% low, 17.1% excessive threat and eight.4% threat free. 38.2% of dangerous contacts occurred whereas working in inner/surgical clinics. Whereas 66.0% of the staff had dangerous contact throughout affected person care and therapy, 25% had dangerous contact with colleagues in social settings. Excessive-risk contact was larger in social relations between workers. The supply of the contact was a colleague in 73.2% of the staff.
The common age of high-risk workers was smaller than these of low-risk. Whereas 54.5% of the staff wore surgical masks throughout contact, 67.8% of the sufferers didn’t have a masks. Of 555 workers adopted, 37 (6.7%) have been recognized as COVID-19; 48.6% of the sufferers have been nurses and 18.9% have been medical doctors. It was decided that 48.6% of the healthcare staff have been working within the COVID-19 service, outpatient clinic or intensive care unit on the time of analysis. The supply of the an infection was regarded as a colleague in 51.6% of the sufferers. COVID-19 was extra widespread in nurses and medical doctors.
It was decided that dangerous contact additionally occurred in companies apart from the models the place COVID-19 sufferers have been handled and dangerous contact usually passed off whereas offering healthcare to the sufferers and through social relations between the staff. Unprotected contact of the staff with one another within the office was recognized as an essential threat supply. Insufficient use of non-public protecting tools by healthcare staff led to a rise in medium and excessive threat contacts. The usage of masks by sufferers and their family members in the course of the well being service supply and the correct use of non-public protecting tools by healthcare professionals will scale back the chance.
Challenges for bronchial asthma models in response to COVID-19: a qualitative group dynamics evaluation
To develop a set of suggestions for the administration of extreme bronchial asthma throughout COVID-19 pandemic. Eleven pneumologists and allergologists who have been employees members of formally accredited bronchial asthma models in Catalonia (Spain) participated in a cross-section examine primarily based on three 2-hour digital workshops (first: brainstorming, second: identification of impacts and challenges summarized in 10 matters, third: institution of ultimate suggestions by consensus).
Impacts and challenges recognized have been enchancment of referral protocols between completely different ranges of care; evaluation of the minimal variety of perform checks to be carried out and promote the efficiency of spirometry in major care; implementation of videoconferencing, cellular apps, phone calls, or integral digital platforms for the follow-up of sufferers, and definition of the mannequin of care (face-to-face, telematics, combined) in keeping with the affected person’s particular person wants; self-administration of biologics for domiciliary therapy; and empowerment of the position of nursing and hospital pharmacy specifically for follow-up and self-administration of biologics.
Alpha-bungarotoxin, CF640r |
|||
9-00004 | Biotium |
|
|
Description: Minimum order quantity: 1 unit of 100uG |
Alpha-bungarotoxin, CF488a |
|||
9-00005 | Biotium |
|
|
Description: Minimum order quantity: 1 unit of 500uG |
Alpha-bungarotoxin CF488a |
|||
9-00005 | Biotium |
|
|
Description: Minimum order quantity: 1 unit of 100uG |
Alpha-bungarotoxin, CF568 |
|||
9-00006 | Biotium |
|
|
Description: Minimum order quantity: 1 unit of 500uG |
Alpha-bungarotoxin, CF568 |
|||
9-00006 | Biotium |
|
|
Description: Minimum order quantity: 1 unit of 100uG |
Alpha-bungarotoxin, CF594 |
|||
9-00007 | Biotium |
|
|
Description: Minimum order quantity: 1 unit of 500uG |
Alpha-bungarotoxin CF594 |
|||
9-00007 | Biotium |
|
|
Description: Minimum order quantity: 1 unit of 100uG |
Alpha-bungarotoxin, CF633 |
|||
9-00009 | Biotium |
|
|
Description: Minimum order quantity: 1 unit of 500uG |
Alpha-bungarotoxin, CF633 |
|||
9-00009 | Biotium |
|
|
Description: Minimum order quantity: 1 unit of 100uG |
Alpha-bungarotoxin |
|||
00010-1 | Biotium | 1MG | EUR 201.6 |
Description: Minimum order quantity: 1 unit of 1MG |
Fluorescein-Alpha-bungarotoxin |
|||
00011 | Biotium | 500uG | EUR 440.4 |
Description: Minimum order quantity: 1 unit of 500uG |
Tetramethylrhodamine-Alpha-bungarotoxin |
|||
00012 | Biotium | 500uG | EUR 459.6 |
Description: Minimum order quantity: 1 unit of 500uG |
Fluorescein-alpha-bungarotoxin: (10x50ug) |
|||
00013 | Biotium | 10ST | EUR 500.4 |
Description: Minimum order quantity: 1 unit of 10ST |
Tetramethylrhodamine-alpha-bungarotoxin: (10x50ug) |
|||
00014 | Biotium | 10ST | EUR 559.2 |
Description: Minimum order quantity: 1 unit of 10ST |
Sulforhodamine 101-a-bungarotoxin (Texas Red--a-bungarotoxin): (500ug) |
|||
00015 | Biotium | 500uG | EUR 559.2 |
Description: Minimum order quantity: 1 unit of 500uG |
Sulforhodamine 101-a-bungarotoxin (Texas Red--a-bungarotoxin): (10x50ug) |
|||
00016 | Biotium | 10ST | EUR 627.6 |
Description: Minimum order quantity: 1 unit of 10ST |
Biotin-xx-a-bungarotoxin |
|||
00017 | Biotium | 500uG | EUR 519.6 |
Description: Minimum order quantity: 1 unit of 500uG |
Alpha-Bungarotoxin, CF555 conjugate |
|||
9-00018 | Biotium |
|
|
Description: Minimum order quantity: 1 unit of 500uG |
Alpha-Bungarotoxin, CF555 conjugate |
|||
9-00018 | Biotium |
|
|
Description: Minimum order quantity: 1 unit of 100ug |
Biotin-cAMP, diisopropylethylammonium salt: |
|||
00020 | Biotium | 1MG | EUR 376.8 |
Description: Minimum order quantity: 1 unit of 1MG |
Biotin-cAMP, diisopropylethylammonium salt: (20x50ug) |
|||
00020-1 | Biotium | 20ST | EUR 501.6 |
Description: Minimum order quantity: 1 unit of 20ST |
Biotin-cGMP, diisopropylethylammonium salt: |
|||
00021 | Biotium | 1MG | EUR 412.8 |
Description: Minimum order quantity: 1 unit of 1MG |
Biotin-cGMP, diisopropylethylammonium salt: (20x50ug) |
|||
00021-1 | Biotium | 20ST | EUR 537.6 |
Description: Minimum order quantity: 1 unit of 20ST |
Cyanine 644-cAMP: |
|||
00022 | Biotium | 1MG | EUR 589.2 |
Description: Minimum order quantity: 1 unit of 1MG |
Cyanine 644-cAMP: (20x50ug) |
|||
00022-1 | Biotium | 20ST | EUR 750 |
Description: Minimum order quantity: 1 unit of 20ST |
Fluorescein Methotrexate, triammonium salt: |
|||
00023 | Biotium | 1MG | EUR 337.2 |
Description: Minimum order quantity: 1 unit of 1MG |
Staurosporine |
|||
00025 | Biotium | 100uG | EUR 166.8 |
Description: Minimum order quantity: 1 unit of 100uG |
Alpha-bungarotoxin, CF543 |
|||
00026 | Biotium | 500uG | EUR 592.8 |
Description: Minimum order quantity: 1 unit of 500uG |
Rhodamine phalloidin 300u |
|||
00027 | Biotium | 300 | EUR 414 |
Description: Minimum order quantity: 1 unit of 300 |
Biotin-xx-phalloidin |
|||
00028 | Biotium | 100U | EUR 513.6 |
Description: Minimum order quantity: 1 unit of 100U |
Fluorescein-phalloidin |
|||
00030 | Biotium | 300U | EUR 414 |
Description: Minimum order quantity: 1 unit of 300U |
Rhodamine 110 phalloidin |
|||
00032 | Biotium | 300ST | EUR 414 |
Description: Minimum order quantity: 1 unit of 300ST |
Sulforhodamine 101 (Texas-Red) Phalloidin |
|||
00033 | Biotium | 300EU | EUR 414 |
Description: Minimum order quantity: 1 unit of 300EU |
Phalloidin, CF405M |
|||
00034 | Biotium | 300U | EUR 530.4 |
Description: Minimum order quantity: 1 unit of 300U |
Phalloidin, CF405M |
|||
00034-T | Biotium | 50U | EUR 159.6 |
Description: Minimum order quantity: 1 unit of 50U |
CF488A-cAMP |
|||
00036 | Biotium | 100ug | EUR 206.4 |
Description: Minimum order quantity: 1 unit of 100ug |
CF640R-cAMP |
|||
00037 | Biotium | 100ug | EUR 206.4 |
Description: Minimum order quantity: 1 unit of 100ug |
Phalloidin, CF555 |
|||
00040 | Biotium | 300U | EUR 530.4 |
Description: Minimum order quantity: 1 unit of 300U |
Phalloidin, CF555 |
|||
00040-T | Biotium | 50U | EUR 159.6 |
Description: Minimum order quantity: 1 unit of 50U |
Phalloidin, CF647 |
|||
00041 | Biotium | 300U | EUR 530.4 |
Description: Minimum order quantity: 1 unit of 300U |
Phalloidin, CF647 |
|||
00041-T | Biotium | 50U | EUR 159.6 |
Description: Minimum order quantity: 1 unit of 50U |
Phalloidin, CF488A |
|||
00042 | Biotium | 300U | EUR 530.4 |
Description: Minimum order quantity: 1 unit of 300U |
Phalloidin, CF488A |
|||
00042-T | Biotium | 50U | EUR 159.6 |
Description: Minimum order quantity: 1 unit of 50U |
Phalloidin, CF543 |
|||
00043 | Biotium | 300U | EUR 530.4 |
Description: Minimum order quantity: 1 unit of 300U |
Phalloidin, CF543 |
|||
00043-T | Biotium | 50U | EUR 159.6 |
Description: Minimum order quantity: 1 unit of 50U |
Phalloidin, CF568 |
|||
00044 | Biotium | 300U | EUR 530.4 |
Description: Minimum order quantity: 1 unit of 300U |
Phalloidin, CF568 |
|||
00044-T | Biotium | 50U | EUR 159.6 |
Description: Minimum order quantity: 1 unit of 50U |
Phalloidin, CF594 |
|||
00045 | Biotium | 300U | EUR 530.4 |
Description: Minimum order quantity: 1 unit of 300U |
Phalloidin, CF594 |
|||
00045-T | Biotium | 50U | EUR 159.6 |
Description: Minimum order quantity: 1 unit of 50U |
Phalloidin, CF633 |
|||
00046 | Biotium | 300U | EUR 530.4 |
Description: Minimum order quantity: 1 unit of 300U |
Phalloidin, CF633 |
|||
00046-T | Biotium | 50U | EUR 159.6 |
Description: Minimum order quantity: 1 unit of 50U |
Phalloidin, CF660R |
|||
00047 | Biotium | 300U | EUR 530.4 |
Description: Minimum order quantity: 1 unit of 300U |
Phalloidin, CF660R |
|||
00047-T | Biotium | 50U | EUR 159.6 |
Description: Minimum order quantity: 1 unit of 50U |
Phalloidin, CF680R |
|||
00048 | Biotium | 300U | EUR 559.2 |
Description: Minimum order quantity: 1 unit of 300U |
Phalloidin, CF680R |
|||
00048-T | Biotium | 50U | EUR 159.6 |
Description: Minimum order quantity: 1 unit of 50U |
Phalloidin, CF350 |
|||
00049 | Biotium | 300U | EUR 530.4 |
Description: Minimum order quantity: 1 unit of 300U |
Phalloidin, CF350 |
|||
00049-T | Biotium | 50U | EUR 159.6 |
Description: Minimum order quantity: 1 unit of 50U |
Phalloidin, CF640R |
|||
00050 | Biotium | 300U | EUR 530.4 |
Description: Minimum order quantity: 1 unit of 300U |
Phalloidin, CF640R |
|||
00050-T | Biotium | 50U | EUR 159.6 |
Description: Minimum order quantity: 1 unit of 50U |
Phalloidin, CF532 |
|||
00051 | Biotium | 300U | EUR 530.4 |
Description: Minimum order quantity: 1 unit of 300U |
Phalloidin, CF532 |
|||
00051-T | Biotium | 50U | EUR 159.6 |
Description: Minimum order quantity: 1 unit of 50U |
Phalloidin, CF660C |
|||
00052 | Biotium | 300U | EUR 530.4 |
Description: Minimum order quantity: 1 unit of 300U |
Phalloidin, CF660C |
|||
00052-T | Biotium | 50U | EUR 159.6 |
Description: Minimum order quantity: 1 unit of 50U |
Phalloidin, CF680 |
|||
00053 | Biotium | 300U | EUR 559.2 |
Description: Minimum order quantity: 1 unit of 300U |
Phalloidin, CF680 |
|||
00053-T | Biotium | 50U | EUR 176.4 |
Description: Minimum order quantity: 1 unit of 50U |
Phalloidin, CF430 |
|||
00054 | Biotium | 300U | EUR 538.8 |
Description: Minimum order quantity: 1 unit of 300U |
Phalloidin, CF430 |
|||
00054-T | Biotium | 50U | EUR 166.8 |
Description: Minimum order quantity: 1 unit of 50U |
Phalloidin, CF440 |
|||
00055 | Biotium | 300U | EUR 538.8 |
Description: Minimum order quantity: 1 unit of 300U |
Phalloidin, CF440 |
|||
00055-T | Biotium | 50U | EUR 166.8 |
Description: Minimum order quantity: 1 unit of 50U |
Cholera Toxin Subunit B, CF488A conjugate |
|||
00070 | Biotium | 100ug | EUR 313.2 |
Description: Minimum order quantity: 1 unit of 100ug |
Cholera Toxin Subunit B, CF568 conjugate |
|||
00071 | Biotium | 100ug | EUR 313.2 |
Description: Minimum order quantity: 1 unit of 100ug |
Cholera Toxin Subunit B, CF594 conjugate |
|||
00072 | Biotium | 100ug | EUR 313.2 |
Description: Minimum order quantity: 1 unit of 100ug |
Cholera Toxin Subunit B, CF640R conjugate |
|||
00073 | Biotium | 100ug | EUR 316.8 |
Description: Minimum order quantity: 1 unit of 100ug |
Cholera Toxin Subunit B, CF532 conjugate |
|||
00074 | Biotium | 100ug | EUR 316.8 |
Description: Minimum order quantity: 1 unit of 100ug |
Cholera Toxin Subunit B, CF543 conjugate |
|||
00075 | Biotium | 100ug | EUR 316.8 |
Description: Minimum order quantity: 1 unit of 100ug |
Cholera Toxin Subunit B, CF620R conjugate |
|||
00076 | Biotium | 100ug | EUR 316.8 |
Description: Minimum order quantity: 1 unit of 100ug |
Cholera Toxin Subunit B, CF633 conjugate |
|||
00077 | Biotium | 100ug | EUR 316.8 |
Description: Minimum order quantity: 1 unit of 100ug |
Cholera Toxin Subunit B, CF660R conjugate |
|||
00078 | Biotium | 100ug | EUR 316.8 |
Description: Minimum order quantity: 1 unit of 100ug |
Cholera Toxin Subunit B, CF680R conjugate |
|||
00079 | Biotium | 100ug | EUR 338.4 |
Description: Minimum order quantity: 1 unit of 100ug |
Human Transferrin, CF488A conjugate |
|||
00081 | Biotium | 1mg | EUR 178.8 |
Description: Minimum order quantity: 1 unit of 1mg |
Human Transferrin, CF543 conjugate |
|||
00082 | Biotium | 1mg | EUR 178.8 |
Description: Minimum order quantity: 1 unit of 1mg |
Human Transferrin, CF568 conjugate |
|||
00083 | Biotium | 1mg | EUR 178.8 |
Description: Minimum order quantity: 1 unit of 1mg |
Human Transferrin, CF594 conjugate |
|||
00084 | Biotium | 1mg | EUR 178.8 |
Description: Minimum order quantity: 1 unit of 1mg |
Human Transferrin, CF640R conjugate |
|||
00085 | Biotium | 1mg | EUR 178.8 |
Description: Minimum order quantity: 1 unit of 1mg |
Human Transferrin, CF680R conjugate |
|||
00086 | Biotium | 1mg | EUR 178.8 |
Description: Minimum order quantity: 1 unit of 1mg |
Human Transferrin, CF750 conjugate |
|||
00087 | Biotium | 1mg | EUR 186 |
Description: Minimum order quantity: 1 unit of 1mg |
HIV-1 tat recombinant antigen |
|||
00110-V-01mg | Virogen | 0,1 mg | EUR 321 |
Description: HIV-1 tat recombinant antigen full length 15 kDa |
HIV-1 tat recombinant antigen |
|||
00110-V-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: HIV-1 tat recombinant antigen full length 15 kDa |
HIV-1 GAG P24 Recombinant Antigen |
|||
00111-V-01mg | Virogen | 0,1 mg | EUR 321 |
Description: HIV-1 gag p24 recombinant antigen a.a 77 to a.a 436 of the HIV-1 gag region 39 kDa |
HIV-1 GAG P24 Recombinant Antigen |
|||
00111-V-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: HIV-1 gag p24 recombinant antigen a.a 77 to a.a 436 of the HIV-1 gag region 39 kDa |
HIV-1 nef recombinant antigen |
|||
00112-V-01mg | Virogen | 0,1 mg | EUR 321 |
Description: HIV-1 nef recombinant antigen a.a 3 to a.a 190 of the HIV-1 nef region 20 kDa |
HIV-1 nef recombinant antigen |
|||
00112-V-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: HIV-1 nef recombinant antigen a.a 3 to a.a 190 of the HIV-1 nef region 20 kDa |
HIV-1 env gp41 recombinant antigen |
|||
00113-V-01mg | Virogen | 0,1 mg | EUR 321 |
Description: HIV-1 env gp41 recombinant antigen a.a 466 to a.a 753 of the HIV-1 env region 32 kDa |
HIV-1 env gp41 recombinant antigen |
|||
00113-V-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: HIV-1 env gp41 recombinant antigen a.a 466 to a.a 753 of the HIV-1 env region 32 kDa |
HIV-2 GP 36 Recombinant Antigen |
|||
00114-V-01mg | Virogen | 0,1 mg | EUR 321 |
Description: HIV -2 env gp36 recombinant antigen a.a 390 to a.a 702 of the HIV-2 env region 34 kDa |
HIV-2 GP 36 Recombinant Antigen |
|||
00114-V-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: HIV -2 env gp36 recombinant antigen a.a 390 to a.a 702 of the HIV-2 env region 34 kDa |
HCV core recombinant antigen |
|||
00115-V-01mg | Virogen | 0,1 mg | EUR 321 |
Description: HCV core recombinant antigen a.a 2 to a.a 192 of HCV polyprotein 22 kDa |
HCV core recombinant antigen |
|||
00115-V-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: HCV core recombinant antigen a.a 2 to a.a 192 of HCV polyprotein 22 kDa |
HCV core recombinant antigen, Biotin conjugate |
|||
00115-V-B-01mg | Virogen | 0,1 mg | EUR 321 |
Description: HCV core recombinant antigen a.a 2 to a.a 192 of HCV polyprotein 22 kDa. Biotin conjugate. |
HCV core recombinant antigen, Biotin conjugate |
|||
00115-V-B-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: HCV core recombinant antigen a.a 2 to a.a 192 of HCV polyprotein 22 kDa. Biotin conjugate. |
HCV core recombinant antigen, FITC conjugate |
|||
00115-V-F-01mg | Virogen | 0,1 mg | EUR 321 |
Description: HCV core recombinant antigen a.a 2 to a.a 192 of HCV polyprotein 22 kDa. Fluorescein conjugate. |
HCV core recombinant antigen, FITC conjugate |
|||
00115-V-F-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: HCV core recombinant antigen a.a 2 to a.a 192 of HCV polyprotein 22 kDa. Fluorescein conjugate. |
HCV core recombinant antigen, Rhodamine |
|||
00115-V-R-01mg | Virogen | 0,1 mg | EUR 321 |
Description: HCV core recombinant antigen a.a 2 to a.a 192 of HCV polyprotein 22 kDa . Rhodamine conjugate. |
HCV core recombinant antigen, Rhodamine |
|||
00115-V-R-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: HCV core recombinant antigen a.a 2 to a.a 192 of HCV polyprotein 22 kDa . Rhodamine conjugate. |
HCV NS4 recombinant antigen NS4a+b |
|||
00116-V-01mg | Virogen | 0,1 mg | EUR 321 |
Description: HCV NS4 recombinant antigen NS4a+b a.a 1658 to a.a 1863 of HCV polyprotein, 19 kDa. |
HCV NS4 recombinant antigen NS4a+b |
|||
00116-V-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: HCV NS4 recombinant antigen NS4a+b a.a 1658 to a.a 1863 of HCV polyprotein, 19 kDa. |
HCV NS4 recombinant antigen NS4a+b, Biotin |
|||
00116-V-B-01mg | Virogen | 0,1 mg | EUR 321 |
Description: HCV NS4 recombinant antigen NS4a+b a.a 1658 to a.a 1863 of HCV polyprotein, 19 kDa. Biotin conjugate. |
HCV NS4 recombinant antigen NS4a+b, Biotin |
|||
00116-V-B-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: HCV NS4 recombinant antigen NS4a+b a.a 1658 to a.a 1863 of HCV polyprotein, 19 kDa. Biotin conjugate. |
HCV NS4 recombinant antigen NS4a+b, FITC |
|||
00116-V-F-01mg | Virogen | 0,1 mg | EUR 321 |
Description: HCV NS4 recombinant antigen NS4a+b a.a 1658 to a.a 1863 of HCV polyprotein, 19 kDa. Fluorescein conjugate. |
HCV NS4 recombinant antigen NS4a+b, FITC |
|||
00116-V-F-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: HCV NS4 recombinant antigen NS4a+b a.a 1658 to a.a 1863 of HCV polyprotein, 19 kDa. Fluorescein conjugate. |
HCV NS4 recombinant antigen NS4a+b, Rhodamine |
|||
00116-V-R-01mg | Virogen | 0,1 mg | EUR 321 |
Description: HCV NS4 recombinant antigen NS4a+b a.a 1658 to a.a 1863 of HCV polyprotein, 19 kDa. Rhodamine conjugate. |
HCV NS4 recombinant antigen NS4a+b, Rhodamine |
|||
00116-V-R-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: HCV NS4 recombinant antigen NS4a+b a.a 1658 to a.a 1863 of HCV polyprotein, 19 kDa. Rhodamine conjugate. |
HCV NS3 recombinant antigen |
|||
00117-V-01mg | Virogen | 0,1 mg | EUR 321 |
Description: HCV NS3 recombinant antigen a.a 1400 to a.a 1643 of HCV polyprotein 22 kDa |
HCV NS3 recombinant antigen |
|||
00117-V-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: HCV NS3 recombinant antigen a.a 1400 to a.a 1643 of HCV polyprotein 22 kDa |
HBV core recombinant antigen |
|||
00120-V-01mg | Virogen | 0,1 mg | EUR 321 |
Description: HBV core recombinant antigen HBcAg a.a 1 to a.a 183 of HBV core antigen 18 kDa |
HBV core recombinant antigen |
|||
00120-V-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: HBV core recombinant antigen HBcAg a.a 1 to a.a 183 of HBV core antigen 18 kDa |
HBV core recombinant antigen, Delta |
|||
00121-V-01mg | Virogen | 0,1 mg | EUR 321 |
Description: HBV core recombinant antigen HBcAg a.a 1 to a.a 144 of HBV core antigen 16 kDa |
HBV core recombinant antigen, Delta |
|||
00121-V-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: HBV core recombinant antigen HBcAg a.a 1 to a.a 144 of HBV core antigen 16 kDa |
HBV surface recombinant antigen HBsAg |
|||
00122-V-01mg | Virogen | 0,1 mg | EUR 321 |
Description: HBV surface recombinant antigen HBsAg antigen 22 kDa Pichia pastoris recombinant |
HBV surface recombinant antigen HBsAg |
|||
00122-V-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: HBV surface recombinant antigen HBsAg antigen 22 kDa Pichia pastoris recombinant |
HBV surface recombinant antigen HBsAg antigen |
|||
00123-V-01mg | Virogen | 0,1 mg | EUR 321 |
Description: HBV surface recombinant antigen HBsAg antigen 22 kDa Pichia pastoris recombinant High purity |
HBV surface recombinant antigen HBsAg antigen |
|||
00123-V-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: HBV surface recombinant antigen HBsAg antigen 22 kDa Pichia pastoris recombinant High purity |
HBV surface recombinant antigen HBsAg antigen |
|||
00124-V-01mg | Virogen | 0,1 mg | EUR 321 |
Description: HBV surface recombinant antigen HBsAg antigen 31 kDa E. coli recombinant |
HBV surface recombinant antigen HBsAg antigen |
|||
00124-V-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: HBV surface recombinant antigen HBsAg antigen 31 kDa E. coli recombinant |
HEV (Birma) ORF2 recombinant antigen |
|||
00131-V-01mg | Virogen | 0,1 mg | EUR 321 |
Description: HEV (Birma) ORF2 recombinant antigen a.a. 633 to a.a 659. |
HEV (Birma) ORF2 recombinant antigen |
|||
00131-V-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: HEV (Birma) ORF2 recombinant antigen a.a. 633 to a.a 659. |
HEV (Birma) ORF2 recombinant antigen |
|||
00132-V-01mg | Virogen | 0,1 mg | EUR 321 |
Description: HEV (Birma) ORF2 recombinant antigen a.a. 403 to a.a 461. |
HEV (Birma) ORF2 recombinant antigen |
|||
00132-V-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: HEV (Birma) ORF2 recombinant antigen a.a. 403 to a.a 461. |
AA 403-461 HEV Birma ORF2 Recombinant Antigen |
|||
00133-V-01mg | Virogen | 0,1 mg | EUR 321 |
Description: HEV (Birma) ORF2 recombinant antigen a.a. 92 to a.a 123. |
AA 403-461 HEV Birma ORF2 Recombinant Antigen |
|||
00133-V-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: HEV (Birma) ORF2 recombinant antigen a.a. 92 to a.a 123. |
T, Pallidum recombinant antigen p15 |
|||
00141-V-01mg | Virogen | 0,1 mg | EUR 321 |
Description: T. Pallidum recombinant antigen p15 (full length) |
T, Pallidum recombinant antigen p15 |
|||
00141-V-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: T. Pallidum recombinant antigen p15 (full length) |
T, Pallidum recombinant antigen p17 |
|||
00142-V-01mg | Virogen | 0,1 mg | EUR 321 |
Description: T. Pallidum recombinant antigen p17 (full length) |
T, Pallidum recombinant antigen p17 |
|||
00142-V-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: T. Pallidum recombinant antigen p17 (full length) |
T, Pallidum recombinant antigen p45 |
|||
00143-V-01mg | Virogen | 0,1 mg | EUR 321 |
Description: T. Pallidum recombinant antigen p45 (full length) |
T, Pallidum recombinant antigen p45 |
|||
00143-V-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: T. Pallidum recombinant antigen p45 (full length) |
T, pallidum recombinant antigen TmpA |
|||
00144-V-01mg | Virogen | 0,1 mg | EUR 321 |
Description: T. Pallidum recombinant antigen TmpA (full length) |
T, pallidum recombinant antigen TmpA |
|||
00144-V-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: T. Pallidum recombinant antigen TmpA (full length) |
HCV core 2-119aa recombinant antigen |
|||
00150-V-01mg | Virogen | 0,1 mg | EUR 321 |
Description: HCV core 2-119aa recombinant antigen. Genotypes available: 1a, 1b, 2a, 2b, 3a, 3b, 3/10, 4, 5, 6a |
HCV core 2-119aa recombinant antigen |
|||
00150-V-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: HCV core 2-119aa recombinant antigen. Genotypes available: 1a, 1b, 2a, 2b, 3a, 3b, 3/10, 4, 5, 6a |
HCV Core 24 Antigen |
|||
00151-V-01mg | Virogen | 0,1 mg | EUR 321 |
Description: HCV core 24 antigen. |
HCV Core 24 Antigen |
|||
00151-V-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: HCV core 24 antigen. |
The primary suggestions included coordination between major care and specialised care session, optimization of lung perform testing, implementation of telemedicine, and the position of nursing and hospital pharmacy. The precise proposals in response to the impact of COVID-19 pandemic centered on 4 areas of curiosity (coordination between major care and specialised care, optimization of lung perform testing, implementation of telemedicine, and empowerment of the position of nursing and hospital pharmacy) could also be generalized to different well being care settings, and assist to introduce new methods of caring bronchial asthma sufferers within the COVID-19 context.
![[Assessment of COVID-19 Risky Contact of Healthcare Workers in an University Hospital]](https://www.des-testbed.net/grd/uploads/2021/04/photo_2020-12-09_23-37-59-146x300.jpg)
Neighborhood-led HIV self-testing for males who’ve intercourse with males in Lebanon: classes discovered and influence of COVID-19
The NAP performed a collection of workshops (July-November 2018) to introduce HIVST companies for healthcare staff working at completely different NGOs. The workshops highlighted that HIVST could be distributed free of charge, that it will be confidential and voluntary, and that individuals have been inspired to inform the NGOs of their outcomes, which might be saved strictly confidential. NGOs collected knowledge anonymously and confidentially from beneficiaries (age, consistency of condom use and HIV testing historical past), who have been requested to name again with the outcomes of their HIVST. On the NAP, knowledge have been mixed, aggregated and analysed.